For over twenty years, Podartis has specialised in the manufacture of footwear, insoles and braces for the prevention and treatment of the main carriage disorders: hallux valgus, hammer toes, rheumatic foot, diabetic foot and the post-operative phase.
We talked about diabetic feet before everyone else which is why we now boast cutting-edge solutions in the field. Our shoes, insoles and socks are all meticulously clinically tested and proven to guarantee the greatest benefit for each risk phase. From prevention to the acute stage.
Our tireless commitment to research, our medical-scientific partnerships with the highest authorities in the field and the various patents protecting our footwear are testimony to Podartis’ mission – helping people to walk better and get more enjoyment out of life.
Podartis came into existence in 2001 in Montebelluna (Italy) and originated from a research group with a strong specialisation in technical orthopaedics led by Dr Buratto, the founder of the firm. The research group dates back to 1988 and carried out its first studies into self-moulding footwear, after which it extended its interest to footwear for the post-operative phase and diabetic feet.
Since its inception, the company has invested heavily in research and development, working in close cooperation with specialists from the medical and technical sector to test the manufactured footwear. Over the years, it has achieved some important milestones:
In 1992 the first post-operative shoe with an extendable off-loading outsole.
In 1994 the first worldwide study on footwear for the diabetic foot.
In 2003 the introduction of the first self-moulding shoe in Flexpell.
In 2004 the first worldwide research project on footwear for the diabetic foot.
In 2006 the presentation of the biomechanical outsole designed to reduce pressure variations during walking.
In 2010 the commendation by the prestigious journal Diabetes Care on the effectiveness of our Stabil D brace in treating foot abscesses.
In 2011, the clinical trial of the “Biomechanics of the diabetic foot” at the Istituto Ortopedico Rizzoli (Rizzoli Orthopaedic Institute).
In 2012 tests with the Italian Special Operations Forces on orthotic insoles.
In 2011-13, the clinical trial on pressure-relieving footwear in the post-surgical phase.
In 2012-2014 the clinical trial on therapeutic shoes with our semi-rigid WellWalk® outsole.
These are some of the reasons why today Podartis is considered to be a lead player in Italy for orthopaedic footwear. As a result of its contribution to science and ongoing European research projects, Podartis boasts an international reputation as a lead player in the field of orthopaedic footwear and insoles for “troublesome” feet (diabetic, rheumatic, etc…)
Today with three research projects underway and all of its product ranges clinically tested, Podartis is an international lodestar for the care and prevention of carriage-related disorders.